Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PANIXINE DISPERDOSE

CEPHALEXIN

Standard Dose
EQ 250MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview PANIXINE DISPERDOSE is listed in Drugs@FDA under application 065100 (ANDA).

Marketing status: Discontinued Active ingredient CEPHALEXIN Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 250MG BASE Sponsor RANBAXY LABS LTD Submission history Latest submission status date: 2003-09-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview PANIXINE DISPERDOSE is listed in Drugs@FDA under application 065100 (ANDA). Marketing status: Discontinued Active ingredient CEPHALEXIN Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 250MG BASE Sponsor RANBAXY LABS LTD Submission history Latest submission status date: 2003-09-11 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
PANIXINE DISPERDOSE (CEPHALEXIN) | Drug Monograph | MedicHelpline